Filing Flows

Filing Flows › Travere Therapeutics (TVTX) › Next earnings date

Travere Therapeutics (TVTX) earnings: missed the estimate

Travere Therapeutics (TVTX) reported on Nov 2, 2026 and missed the EPS estimate: −$0.31 against $0.42 (-174.3%). Revenue was $225M for Q3 2026, +36% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−174.3% vs estimate
Beat rate60%

The last report

Travere Therapeutics reported revenue of $225M for the third quarter 2026 (+36% Y/Y), net loss $52.3M: Total net product sales $220M, License and collaboration revenue $4.4M. How it makes money → · Every quarter →

Travere Therapeutics: EPS against the estimate, last 5 reportsTravere Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.09$0.59Oct 25$0.01$0.03Feb 26−$0.06$0.05May 26$0.32−$0.10Aug 26$0.42−$0.31Nov 26
Latest (Nov 26): Estimate $0.42, Reported −$0.31.

Travere Therapeutics' latest quarter

Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Travere Therapeutics beat earnings?

Travere Therapeutics (TVTX) reported on Nov 2, 2026 and missed the EPS estimate: −$0.31 against $0.42 (-174.3%).

When does TVTX report earnings?

The next date is not set yet.

Does Travere Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.